New Portfolio Positions: SAP and adidas

Magellan Investment Partners, recently recommended two new positions to the portfolio, both listed in Germany: SAP (SAP.ETR) and adidas (ADS.ETR). 

New Portfolio Positions: SAP and adidas

January 12, 2026
Magellan Investment Partners, recently recommended two new positions to the portfolio, both listed in Germany: SAP (SAP.ETR) and adidas (ADS.ETR). 
Read Transcript

One of our Core Fund Managers, Magellan Investment Partners (Magellan), recently recommended two new positions to the portfolio, both listed in Germany: SAP (SAP.ETR) and adidas (ADS.ETR). SAP provides enterprise software used to run core business operations, while adidas is a global sportswear company spanning performance and lifestyle products.

Magellan view SAP as an attractive long-term investment underpinned by i) significant revenue uplift as it transitions its customer base from on-premise to the cloud where it remains early in the journey, ii) the ability to sustain healthy revenue growth post this transition through innovation led price increases including AI functionality and continued cross-sell and upsell, and iii) healthy revenue growth and retiring of legacy products supporting meaningful margin expansion towards peer levels. Magellan think the market is currently providing an attractive entry point given a short-term focus on quarterly cloud revenue and backlog growth which is being negatively impacted by the heightened uncertainty earlier in the year around tariffs, US government spending cuts, and the broader macro environment. While not immune from the macro environment, Magellan largely view this as a pushout of customer migrations with limited implications for long-term profits and cashflows. SAP is also being impacted by software wide concerns around AI disruption which Magellan consider misplaced for SAP specifically.

Magellan view adidas as undervalued quality. adidas is a strong number two player in the sports & lifestyle footwear and apparel industry which grows above GDP. While a competitive industry that can see new entrants and impacts from fashion cycles, Magellan believe adidas’s brand, football heritage and scale enable it to remain an industry leader and has seen it take share over time and build a geographically diversified business. While less well positioned in the US given Nike’s dominance, the US is a small proportion of profits and more opportunity than threat. Near-term market concerns around macro conditions, a resurgent Nike, rising inventory levels, and ageing lifestyle products combined with conservative guidance, poor management communication, and looking back to 2022 issues have created in our opinion an attractive entry point. While some of these near-term concerns are warranted, Magellan believe they are more than fairly reflected in adidas’ share price, which combined with historically counter cyclical PEs provide downside protection should they occur and an attractive opportunity if they do not. adidas also has a strong balance sheet and is expected to start buying back its shares in 2026.

One of our Core Fund Managers, Magellan Investment Partners (Magellan), recently recommended two new positions to the portfolio, both listed in Germany: SAP (SAP.ETR) and adidas (ADS.ETR). SAP provides enterprise software used to run core business operations, while adidas is a global sportswear company spanning performance and lifestyle products.

Magellan view SAP as an attractive long-term investment underpinned by i) significant revenue uplift as it transitions its customer base from on-premise to the cloud where it remains early in the journey, ii) the ability to sustain healthy revenue growth post this transition through innovation led price increases including AI functionality and continued cross-sell and upsell, and iii) healthy revenue growth and retiring of legacy products supporting meaningful margin expansion towards peer levels. Magellan think the market is currently providing an attractive entry point given a short-term focus on quarterly cloud revenue and backlog growth which is being negatively impacted by the heightened uncertainty earlier in the year around tariffs, US government spending cuts, and the broader macro environment. While not immune from the macro environment, Magellan largely view this as a pushout of customer migrations with limited implications for long-term profits and cashflows. SAP is also being impacted by software wide concerns around AI disruption which Magellan consider misplaced for SAP specifically.

Magellan view adidas as undervalued quality. adidas is a strong number two player in the sports & lifestyle footwear and apparel industry which grows above GDP. While a competitive industry that can see new entrants and impacts from fashion cycles, Magellan believe adidas’s brand, football heritage and scale enable it to remain an industry leader and has seen it take share over time and build a geographically diversified business. While less well positioned in the US given Nike’s dominance, the US is a small proportion of profits and more opportunity than threat. Near-term market concerns around macro conditions, a resurgent Nike, rising inventory levels, and ageing lifestyle products combined with conservative guidance, poor management communication, and looking back to 2022 issues have created in our opinion an attractive entry point. While some of these near-term concerns are warranted, Magellan believe they are more than fairly reflected in adidas’ share price, which combined with historically counter cyclical PEs provide downside protection should they occur and an attractive opportunity if they do not. adidas also has a strong balance sheet and is expected to start buying back its shares in 2026.

Disclaimer: This material has been prepared by Hearts & Minds Investments, published on Jan 12, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 6, 2024

Exploring HM1 Top Stocks: Key Insights from Reporting Season

We have just come to the end of reporting season and the fund managers of our major portfolio holdings gave us their insights into the latest results of our key holdings.

Read More
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
March 7, 2024

Exploring HM1 Stocks: Key Insights from Reporting Season

We asked our fund managers for an update on how some of our key positions are performing off the back of the reporting season. Overall, it was a good period for the fund with some good moves to the upside.

Read More
February 6, 2024

Stock Story: ResMed

This month we take a deep dive into ResMed - one of the conference stocks within the fund that was astutely picked by Chris Kourtis of Ellerston Capital.

Read More
Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.Ms Lorraine Berends. Director Qantas Super Fund, Pinnacle Investment Management Received an AM in the 2024 Australia Day Honours.
January 25, 2024

Australia Day Honours: Lorraine Berends of Qantas Super

Congratulations to our Board of Director, Lorraine Berends, who was awarded AM in the Australia Day honours.

Read More
January 25, 2024

Fowler toasts Sohn legacy

Grounds, Fowler, and Weiss set up the Australian version, the Sohn Hearts & Minds conference in 2016, with the first meeting at the Sydney Opera House.

Read More
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
December 5, 2023

Guzman y Gomez | Performance Update

Guzman y Gomez (GYG) held its Annual General Meeting on 30 November and provided an update on its FY24 year-to-date results.

Read More
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.